Cloned by Viagen in 2023 from cells frozen for more than 40 years, “Ollie,” a Przewalski’s horse foal shown here at five days old, marks another milestone in using biotechnology to help restore threatened animal populations. [Photo: Elizabeth Arellano Photography/Viagen]
The de-extinction startup is adding more than two decades of commercial cloning expertise to its portfolio with its first acquisition.
Days before the announcement, CEO Ben Lamm laid out his playbook at Venture Dallas 2025: run toward critics, treat promises to middle-America classrooms as seriously as commitments to investors—and spin out businesses worth more than $100 million.